

(51) Internationale Patentklassifikation ⁷ :C12N 15/12, C07K 14/705, 16/28, G01N
33/68, A61K 38/17, A01K 67/027, A61K
49/00

A3

(11) Internationale Veröffentlichungsnummer: WO 00/15784

(43) Internationales
Veröffentlichungsdatum:

23. März 2000 (23.03.00)

(21) Internationales Aktenzeichen: PCT/DE99/02871

(22) Internationales Anmeldedatum: 10. September 1999
(10.09.99)

(30) Prioritätsdaten:

198 43 240.2 11. September 1998 (11.09.98) DE
198 46 979.9 13. Oktober 1998 (13.10.98) DE(71) Anmelder (für alle Bestimmungsstaaten ausser US):
MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE
MEDIZIN [DE/DE]; Robert-Rössle-Strasse 10, D-13125
Berlin (DE).

(72) Erfinder; und

(75) Erfinder/Anmelder (nur für US): GRÄLER, Markus [DE/DE];
Genthiner Strasse 30b, D-10785 Berlin (DE). BERN-
HARDT, Günter [DE/DE]; Börnestrasse 38, D-13086
Berlin (DE). LIPP, Martin [DE/DE]; Tulpenstrasse 31,
D-16548 Glienicke (DE).(74) Anwalt: BAUMBACH, Fritz; BioTez Berlin-Buch GmbH,
Patentstelle, Robert-Rössle-Strasse 10, D-13125 Berlin
(DE).(81) Bestimmungsstaaten: JP, US, europäisches Patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

Veröffentlicht

Mit internationalem Recherchenbericht.

(88) Veröffentlichungsdatum des internationalen Recherchenbe-
richts: 17. August 2000 (17.08.00)(54) Title: HUMAN AND MURINE G-PROTEIN-COUPLED EDG6 RECEPTOR (ENDOTHELIAL DIFFERENTIATION GENE) AND
USE OF SAME(54) Bezeichnung: HUMANER UN MURINER G-PROTEIN GEKOPPELTER REZEPTOR EDG6 (ENDOTHELIAL
DIFFERENTIATION GEN) UND SEINE VERWENDUNG

(57) Abstract

The invention relates to the G protein-coupled EDG6 receptor, fragments, variants and mutations thereof, as well as to its use. Areas of application of the invention include molecular biology, pharmacy and medicine. The aim of the invention is to isolate and identify a further member of the family of EDG receptors and to permit its use for medical purposes. The new human EDG6 receptor comprises 384 amino acids of sequence I having seven transmembrane domains. The receptor has a possible N-terminal glycolysis site, three possible palmitoylation sites, between 12 and 15 amino acids in the C-terminal position of the seventh transmembrane domain and four possible C-terminal protein kinase C-phosphorylation sites. The invention further relates to the use of the EDG6 receptor, its fragments, variants and mutations and possibly its binding partners for therapeutic methods and treatments.

